Peer-reviewed article
First-Line Tocilizumab Monotherapy for Juvenile Systemic Sclerosis With Interstitial Lung Disease: A Case Report.
Yokoyama T, Inoue N, Watanabe S, Matsushita T, Wada T ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a medical case report about a single 12-year-old child treated with tocilizumab for juvenile systemic sclerosis with lung disease. The child's lung function remained stable over 3 years of treatment with no serious side effects. The report suggests tocilizumab may be worth considering for this rare condition but calls for further research.
Key points
- A 12-year-old Japanese girl with systemic sclerosis and interstitial lung disease was treated with tocilizumab monotherapy
- Over 3 years of follow-up, pulmonary function remained stable and lung imaging showed partial improvement
- No serious adverse events such as severe infections or low blood cell counts were observed
- Systemic sclerosis is rare in children but often presents aggressively with high risk of lung disease
Limitations
This is a single case report of one child, so it cannot establish whether the treatment works broadly or compare it to other treatments. The authors themselves acknowledge that evidence in pediatric cases remains extremely limited and call for further studies.
Abstract
Systemic sclerosis, a rare autoimmune disease in children, frequently presents with aggressive clinical features and high risk of interstitial lung disease. Tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, has exhibited efficacy in adult systemic sclerosis with interstitial lung disease; however, evidence in pediatric cases remains extremely limited. We report a 12-year-old Japanese girl who developed early-stage juvenile systemic sclerosis with interstitial lung disease, presenting with Raynaud's phenomenon, puffy fingers, positive anti-topoisomerase I antibody, reduced pulmonary function, and ground-glass opacities on high-resolution computed tomography. Consequently, tocilizumab monotherapy was initiated. During a follow-up period of over 3 years, her pulmonary function remained stable, and high-resolution computed tomography showed partial resolution of interstitial changes. No significant adverse events, such as severe infections or cytopenias, were observed. Early tocilizumab initiation may represent a potential therapeutic option for juvenile systemic sclerosis with interstitial lung disease. However, further studies are warranted to validate its role and optimize treatment guidelines for this rare but severe condition.